Exact Mass: 363.1576
Exact Mass Matches: 363.1576
Found 86 metabolites which its exact mass value is equals to given mass value 363.1576,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
(2S)-1-[(2S)-3-(4H-Imidazol-4-yl)-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carboxylic acid
(2S)-1-[(2S)-3-(4H-Imidazol-4-yl)-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carboxylic acid
N-((Tetrahydro-5-oxo-2-furanyl)carbonyl)-L-histidyl-L-prolinamide
1-[3-(1H-imidazol-5-yl)-2-[(5-oxooxolane-2-carbonyl)amino]propanoyl]pyrrolidine-2-carboxamide
Pglu-his-pro
1-(2-{[hydroxy(5-hydroxy-3,4-dihydro-2H-pyrrol-2-yl)methylidene]amino}-3-(1H-imidazol-5-yl)propanoyl)pyrrolidine-2-carboxylate
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones Thyrotropin-Releasing Hormone (TRH), Free Acid (TRH-OH) is a physiological metabolite of Thyrotropin-Releasing Hormone.
C21H21N3O3_8,8-Dimethyl-5a,6-dihydro-3H,5H,8H-spiro[indole-2,7-pyrrolo[1,2:4,5]pyrazino[1,2-a]azepine]-3,5,12(1H,2H)-trione
NCGC00380729-01_C21H21N3O3_8,8-Dimethyl-5a,6-dihydro-3H,5H,8H-spiro[indole-2,7-pyrrolo[1,2:4,5]pyrazino[1,2-a]azepine]-3,5,12(1H,2H)-trione
Cys Gly Gly Lys
(2S)-6-amino-2-(2-{2-[(2R)-2-amino-3-sulfanylpropanamido]acetamido}acetamido)hexanoic acid
Cys Gly Lys Gly
2-[(2S)-6-amino-2-{2-[(2R)-2-amino-3-sulfanylpropanamido]acetamido}hexanamido]acetic acid
Cys Lys Gly Gly
2-{2-[(2S)-6-amino-2-[(2R)-2-amino-3-sulfanylpropanamido]hexanamido]acetamido}acetic acid
Gly Cys Gly Lys
(2S)-6-amino-2-{2-[(2R)-2-(2-aminoacetamido)-3-sulfanylpropanamido]acetamido}hexanoic acid
Gly Cys Lys Gly
2-[(2S)-6-amino-2-[(2R)-2-(2-aminoacetamido)-3-sulfanylpropanamido]hexanamido]acetic acid
Gly Gly Cys Lys
(2S)-6-amino-2-[(2R)-2-[2-(2-aminoacetamido)acetamido]-3-sulfanylpropanamido]hexanoic acid
Gly Gly Lys Cys
(2R)-2-[(2S)-6-amino-2-[2-(2-aminoacetamido)acetamido]hexanamido]-3-sulfanylpropanoic acid
Gly Lys Cys Gly
2-[(2R)-2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]-3-sulfanylpropanamido]acetic acid
Gly Lys Gly Cys
(2R)-2-{2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]acetamido}-3-sulfanylpropanoic acid
Lys Cys Gly Gly
2-{2-[(2R)-2-[(2S)-2,6-diaminohexanamido]-3-sulfanylpropanamido]acetamido}acetic acid
Lys Gly Cys Gly
2-[(2R)-2-{2-[(2S)-2,6-diaminohexanamido]acetamido}-3-sulfanylpropanamido]acetic acid
Lys Gly Gly Cys
(2R)-2-(2-{2-[(2S)-2,6-diaminohexanamido]acetamido}acetamido)-3-sulfanylpropanoic acid
3-HYDROXY-2,3-DIMETHYLBUTAN-2-YL HYDROGEN (3-((1,3-DIOXOISOINDOLIN-2-YL)METHYL)PHENYL)BORONATE
3-HYDROXY-2,3-DIMETHYLBUTAN-2-YL HYDROGEN (3-((1,3-DIOXOISOINDOLIN-2-YL)METHYL)PHENYL)BORONATE
(2-PHTALIMIDOMETHYLPHENYL)BORONIC ACID, PINACOL ESTER
(2-PHTALIMIDOMETHYLPHENYL)BORONIC ACID, PINACOL ESTER
Urea, N-[2-[(3-cyano-8-methyl-2-quinolinyl)amino]ethyl]-N-(4-fluorophenyl)- (9CI)
Urea, N-[2-[(3-cyano-8-methyl-2-quinolinyl)amino]ethyl]-N-(4-fluorophenyl)- (9CI)
Urea, N-[2-[(3-cyano-8-methyl-2-quinolinyl)amino]ethyl]-N-(2-fluorophenyl)- (9CI)
Urea, N-[2-[(3-cyano-8-methyl-2-quinolinyl)amino]ethyl]-N-(2-fluorophenyl)- (9CI)
[2-(dimethylamino)-2-methylpropyl] 2-hydroxy-2,2-diphenylacetate,hydrochloride
[2-(dimethylamino)-2-methylpropyl] 2-hydroxy-2,2-diphenylacetate,hydrochloride
(4-PHTHALIMIDOMETHYLPHENYL)BORONIC ACID, PINACOL ESTER
(4-PHTHALIMIDOMETHYLPHENYL)BORONIC ACID, PINACOL ESTER
Ozenoxacin
Ozenoxacin
D - Dermatologicals > D06 - Antibiotics and chemotherapeutics for dermatological use > D06A - Antibiotics for topical use C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents D004791 - Enzyme Inhibitors
4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1,2,3,6-tetrahydropyridine
4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1,2,3,6-tetrahydropyridine
2-[4-(1-adamantyl)-N-methylsulfonylanilino]acetic acid
2-[4-(1-adamantyl)-N-methylsulfonylanilino]acetic acid
Protuboxepin B
Protuboxepin B
An organic heterotricyclic compound that is 10,11-dihydro-6H-oxepino[2,3-d]pyrazino[1,2-a]pyrimidine-6,9(8H)-dione substituted by a benzyl group at position 8 and an isopropyl group at position 11. It has been isolated from Aspergillus species.
2-[(4-amino-5-cyclohexyl-1,2,4-triazol-3-yl)thio]-N-(3-fluoro-4-methylphenyl)acetamide
2-[(4-amino-5-cyclohexyl-1,2,4-triazol-3-yl)thio]-N-(3-fluoro-4-methylphenyl)acetamide
(5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime
(5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime
(2S)-1-[(2S)-3-(4H-Imidazol-4-yl)-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carboxylic acid
(2S)-1-[(2S)-3-(4H-Imidazol-4-yl)-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carboxylic acid
6-(1,3-benzodioxol-5-yl)-N-(3-oxanylmethyl)-4-quinazolinamine
6-(1,3-benzodioxol-5-yl)-N-(3-oxanylmethyl)-4-quinazolinamine
(9S,11R)-12,12-dimethylspiro[1,7-diazatricyclo[7.5.0.03,7]tetradeca-3,13-diene-11,2-1H-indole]-2,3,8-trione
(9S,11R)-12,12-dimethylspiro[1,7-diazatricyclo[7.5.0.03,7]tetradeca-3,13-diene-11,2-1H-indole]-2,3,8-trione
2-[[2-[1-(2-methoxyethyl)-2,5-dimethyl-3-pyrrolyl]-2-oxoethyl]thio]-6-propyl-1H-pyrimidin-4-one
2-[[2-[1-(2-methoxyethyl)-2,5-dimethyl-3-pyrrolyl]-2-oxoethyl]thio]-6-propyl-1H-pyrimidin-4-one
6-(1,3-benzodioxol-5-yl)-N-(2-oxanylmethyl)-4-quinazolinamine
6-(1,3-benzodioxol-5-yl)-N-(2-oxanylmethyl)-4-quinazolinamine
2-[(3R,4S)-3-[[5-(methoxymethyl)-1,2-oxazol-3-yl]methyl]piperidin-4-yl]-N-(thiophen-2-ylmethyl)acetamide
2-[(3R,4S)-3-[[5-(methoxymethyl)-1,2-oxazol-3-yl]methyl]piperidin-4-yl]-N-(thiophen-2-ylmethyl)acetamide
[(1-amino-2-naphthalen-1-ylethylidene)amino] N-(2-ethoxyphenyl)carbamate
[(1-amino-2-naphthalen-1-ylethylidene)amino] N-(2-ethoxyphenyl)carbamate
E1231
E1231
E1231 is an orally active activator of Sirtuin 1 (SIRT1) (EC50=0.83 μM), to modulate cholesterol and lipid metabolism. E1231 interactes with SIRT1 (KD=9.61 μM) and deacetylated liver X receptor-alpha (LXRα), and increases ATP-binding cassette transporter A1 (ABCA1) expression. E1231 also reduces atherosclerotic plaque development in ApoE-/- mice model. E1231 can be used for research in cholesterol and lipid disorder-related diseases[1]. E1231 is an orally active activator of Sirtuin 1 (SIRT1) (EC50=0.83 μM), to modulate cholesterol and lipid metabolism. E1231 interactes with SIRT1 (KD=9.61 μM) and deacetylated liver X receptor-alpha (LXRα), and increases ATP-binding cassette transporter A1 (ABCA1) expression. E1231 also reduces atherosclerotic plaque development in ApoE-/- mice model. E1231 can be used for research in cholesterol and lipid disorder-related diseases[1].
2-hydroxy-6'-(2-methylprop-1-en-1-yl)-1',7'-diazaspiro[indole-3,5'-tricyclo[7.3.0.0³,⁷]dodecan]-3'-ene-2',8'-dione
2-hydroxy-6'-(2-methylprop-1-en-1-yl)-1',7'-diazaspiro[indole-3,5'-tricyclo[7.3.0.0³,⁷]dodecan]-3'-ene-2',8'-dione
5-hydroxy-6-[(4-hydroxyphenyl)methyl]-3-(1h-indol-3-ylmethyl)-1-methyl-3,6-dihydropyrazin-2-one
5-hydroxy-6-[(4-hydroxyphenyl)methyl]-3-(1h-indol-3-ylmethyl)-1-methyl-3,6-dihydropyrazin-2-one
(4s,7r)-7-benzyl-6-hydroxy-4-isopropyl-15-oxa-2,5,8-triazatricyclo[8.5.0.0³,⁸]pentadeca-1(10),2,5,11,13-pentaen-9-one
(4s,7r)-7-benzyl-6-hydroxy-4-isopropyl-15-oxa-2,5,8-triazatricyclo[8.5.0.0³,⁸]pentadeca-1(10),2,5,11,13-pentaen-9-one
methyl 14-(hydroxymethyl)-3,13,17-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,15(20),16,18-heptaene-19-carboxylate
methyl 14-(hydroxymethyl)-3,13,17-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,15(20),16,18-heptaene-19-carboxylate
(3s,6's,9's)-2-hydroxy-6'-(2-methylprop-1-en-1-yl)-1',7'-diazaspiro[indole-3,5'-tricyclo[7.3.0.0³,⁷]dodecan]-3'-ene-2',8'-dione
(3s,6's,9's)-2-hydroxy-6'-(2-methylprop-1-en-1-yl)-1',7'-diazaspiro[indole-3,5'-tricyclo[7.3.0.0³,⁷]dodecan]-3'-ene-2',8'-dione
(9's)-12',12'-dimethyl-1h-1',7'-diazaspiro[indole-2,11'-tricyclo[7.5.0.0³,⁷]tetradecane]-3',13'-diene-2',3,8'-trione
(9's)-12',12'-dimethyl-1h-1',7'-diazaspiro[indole-2,11'-tricyclo[7.5.0.0³,⁷]tetradecane]-3',13'-diene-2',3,8'-trione
12',12'-dimethyl-1h-1',7'-diazaspiro[indole-2,11'-tricyclo[7.5.0.0³,⁷]tetradecane]-3',13'-diene-2',3,8'-trione
12',12'-dimethyl-1h-1',7'-diazaspiro[indole-2,11'-tricyclo[7.5.0.0³,⁷]tetradecane]-3',13'-diene-2',3,8'-trione
(2s,9's)-12',12'-dimethyl-1h-1',7'-diazaspiro[indole-2,11'-tricyclo[7.5.0.0³,⁷]tetradecane]-3',13'-diene-2',3,8'-trione
(2s,9's)-12',12'-dimethyl-1h-1',7'-diazaspiro[indole-2,11'-tricyclo[7.5.0.0³,⁷]tetradecane]-3',13'-diene-2',3,8'-trione
6,7-dimethoxy-4-(4-methoxyphenyl)-1-methyl-3h-naphtho[2,3-d]imidazol-2-imine
6,7-dimethoxy-4-(4-methoxyphenyl)-1-methyl-3h-naphtho[2,3-d]imidazol-2-imine
n-(2-{2-[1-(dimethylamino)-2-phenylethyl]-1,3-oxazole-5-carbonyl}phenyl)carboximidic acid
n-(2-{2-[1-(dimethylamino)-2-phenylethyl]-1,3-oxazole-5-carbonyl}phenyl)carboximidic acid
7-benzyl-6-hydroxy-4-isopropyl-15-oxa-2,5,8-triazatricyclo[8.5.0.0³,⁸]pentadeca-1(10),2,5,11,13-pentaen-9-one
7-benzyl-6-hydroxy-4-isopropyl-15-oxa-2,5,8-triazatricyclo[8.5.0.0³,⁸]pentadeca-1(10),2,5,11,13-pentaen-9-one
(3s,6s)-5-hydroxy-6-[(4-hydroxyphenyl)methyl]-3-(1h-indol-3-ylmethyl)-1-methyl-3,6-dihydropyrazin-2-one
(3s,6s)-5-hydroxy-6-[(4-hydroxyphenyl)methyl]-3-(1h-indol-3-ylmethyl)-1-methyl-3,6-dihydropyrazin-2-one
(1r,2r,4s,5r,7r,12r,15s,23r)-4-amino-18-methoxy-6-oxa-8,16-diazaoctacyclo[10.10.1.0¹,¹⁵.0²,⁷.0⁴,¹⁵.0⁵,¹².0⁸,²³.0¹⁷,²²]tricosa-10,17(22),18,20-tetraen-3-one
(1r,2r,4s,5r,7r,12r,15s,23r)-4-amino-18-methoxy-6-oxa-8,16-diazaoctacyclo[10.10.1.0¹,¹⁵.0²,⁷.0⁴,¹⁵.0⁵,¹².0⁸,²³.0¹⁷,²²]tricosa-10,17(22),18,20-tetraen-3-one
